lncRNA‑MALAT1 expression in patients with coronary atherosclerosis and its predictive value for in‑stent restenosis

Abstract

This study was designed to investigate the long non-coding RNA (lncRNA)-metastasis associated lung adenocarcinoma transcript 1 (MALAT1) expression in patients with coronary atherosclerosis and its predictive value for in-stent restenosis. Ninety-five patients with coronary heart disease who came to our hospital for treatment and underwent stent implantation were selected as a research group (RG), and 95 volunteers undergoing physical examination who did not suffer from coronary heart disease during the same period were selected as a control group (CG). MALAT1 of subjects in both groups before and after treatment were detected by RT-qPCR, and N-terminal pro-brain natriuretic peptide (NT-proBNP), high sensitivity C-reactive protein (hs-CRP), lactate dehydrogenase (LDH), and creatine kinase isoenzyme (CK-MB) of them in the RG before treatment were detected. The level was evaluated and detected, and its correlation with MALAT1 was analyzed. Then, the predictive value of MALAT1 for in-stent restenosis in patients with coronary heart disease was analyzed. MALAT1 expression in patients with coronary heart disease was higher than that of normal subjects (P<0.05); after treatment, the expression levels of MALAT1, NT-proBNP, hs-CRP, LDH, and CK-MB in the serum of patients were significantly lower than those before treatment (P<0.05); MALAT1 expression was positively correlated with the expression levels of NT-proBNP, hs-CRP, LDH, and CK-MB (P<0.05). Receiver operating characteristic of MALAT1 for predicting in-stent restenosis in patients with coronary heart disease was over 0.8; the number of lesions, MALAT1, diabetes, NT-proBNP and hs-CRP were independent risk factors for in-stent restenosis. MALAT1 is highly expressed in the serum of patients with coronary heart disease, and it has high value in its diagnosis and the prediction of in-stent restenosis. It is also an independent risk factor for in-stent restenosis in patients with coronary heart disease.

Upregulation of LncRNAs THRIL and Malat1 in Peripheral Blood of Ischemic Stroke Patients with Large Artery Atherosclerotic and Small Vessel Disease

“…According to previous evidence that demonstrated Malat1 and THRIL expressions were upregulated in atherosclerotic patients with coronary artery diseases [18,19,21,28] we hypothesized that in patients with atherosclerotic IS Malat1 and THRIL expression may be upregulated although present results supported our hypothesis this is in contradiction with Ren's study, This controversy could be attributed to the types of stroke and/or time of blood sampling. We had 59 IS cases with LAA and SVD while in Ren's study the Malat1 level was assessed in 120 IS patients with all types of stroke.…”

“…Malat1 accelerates the accumulation of cholesterol-lled foam cells in blood vessels and enhances lipid uptake in macrophages by CD36 expression and subsequently promotes the atherosclerosis process [20]. Recent studies have identi ed the overexpression of Malat1 in patients with CAD while has shown its predictive value for in-stent restenosis, positive correlation with in ammatory factors, and regulation of coronary slow ow endothelial dysfunction [18,19,21].…”

“…Several studies have demonstrated the signi cant relations of Malat1 and THRIL in the pathogenesis of in ammation, atherosclerosis, and endothelial cell dysfunction [28-35] and a signi cant increase of Malat1 and THRIL have been also reported in the peripheral blood of atherosclerotic patients with CAD [18, 21,25,36]. Nevertheless, their expression in IS, especially in atherosclerotic stroke is still uncertain, with only one study analyzing the blood levels of Malat1 in IS patients (all etiologies) within 24 hours from onset [37].…”

Association of Angio-LncRNAs MIAT rs1061540/MALAT1 rs3200401 Molecular Variants with Gensini Score in Coronary Artery Disease Patients Undergoing Angiography

“…It was significantly upregulated in the blood of CAD patients of different clinical phenotypes and associated with disease severity [ 13 , 46 , 47 , 48 ]. Moreover, recent research has indicated that MALAT1 could not only be a helpful diagnostic cardiac biomarker but also valuable for the prediction of in-stent restenosis [ 49 ].…”

Diagnostic and prognostic significance of lncRNA SOX2-OT in patients with carotid atherosclerosis

“…For instance, serum lncRNA-AWPPH is an independent risk factor for coronary artery disease and lncRNA THRIL is positively related to the accumulating rate of major adverse cardiovascular events in patients with coronary heart disease [ 14 , 15 ]. An analysis manifests that the expression of lncRNA MALAT1 is elevated in humans with coronary atherosclerosis and has prognostic significance for in-stent restenosis [ 16 ]. LncRNA Sox2 overlapping transcript (SOX2-OT) is an lncRNA located in human chromosome 3q26.33 locus.…”